Additional file 2: Figure S2. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

(A/B) Western Blot quantification of Fig. 1d and 1G, n = 3, using FusionCapt 7.06 (Vilber Lourmat, Germany). (PDF 184 kb)